课题基金 / 基金详情

Oral Vaccine-Induced Cellular Immunity Against HIV-1

Oral Vaccine-Induced Cellular Immunity Against HIV-1
口服疫苗诱导的针对 HIV-1 的细胞免疫
批准号:
6408853
负责人:
David Michael Hone
金额:
$37.13万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-30 至 2003-09-29

项目摘要

项目成果

David Michael Hone的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本提案的长期目标是 开发一种沙门氏菌HIV-1 DNA疫苗载体, 粘膜和全身的细胞介导的抗HIV-1免疫应答 免疫区室开发这些载体的理由来自于 越来越多的证据表明粘膜免疫可能 在预防性行为感染HIV-1方面发挥重要作用。 此外,尽管胃肠外给药可以增强粘膜反应, 免疫原,诱导强粘膜免疫应答需要粘膜 启动在这方面,我们已经表明,胃内接种一种 沙门氏菌Env DNA疫苗载体产生Env特异性CD 8 + T细胞, 粘膜和全身淋巴组织。相比之下,肌肉注射疫苗 Env DNA疫苗仅诱导全身性CD 8 + T细胞对Env的应答, 淋巴组织因此,这一建议的核心假设是, 沙门氏菌HIV-1 DNA疫苗载体在启动粘膜免疫方面更有效 免疫反应的HIV-1抗原比肠胃外HIV-1 DNA疫苗。我们将 解决我们的中心假设,并实现这一建议的长期目标, 完成以下具体目标:1.构建DNA疫苗, 共表达HIV-1抗原和粘膜佐剂; 2:鉴定沙门氏菌 HIV-1 DNA疫苗诱导的体液和细胞免疫应答 在粘膜和全身免疫区室中; 3.以确定是否 预先存在的对沙门氏菌的免疫力降低了 沙门氏菌HIV-1 DNA疫苗载体; 4:为了测量 使用选定沙门氏菌载体的一系列初免-加强疫苗接种方案 在目标1至3中发展的结构。总的来说,我们认为这些研究 本文提出的方法将进一步推进该载体系统向广泛应用的方向发展。 在发展中国家和发达国家的临床应用。
英文摘要
DESCRIPTION (Provided by Applicant): The long-term goal of this proposal is to develop a Salmonella HIV-1 DNA vaccine vector that elicits humoral and cell-mediated immune responses against HIV-1, both in the mucosal and systemic immune compartments. Rationale for the development of these vectors stems from an increasing body of evidence indicating that mucosal immunity is likely to play a significant role in protection against sexually acquired HIV-1. Furthermore, although it is possible to boost mucosal responses with parenteral immunogens, induction of strong mucosal immune responses requires mucosal priming. In this vein, we have shown that intragastric vaccination with a Salmonella Env DNA vaccine vector generates Env-specific CD8+ T cells, in both mucosal and systemic lymphoid tissues. By contrast, intramuscular vaccination with the Env DNA vaccine only induces a CD8+ T cell response to Env in systemic lymphoid tissues. The central hypothesis of this proposal, therefore, is that Salmonella HIV-1 DNA vaccine vectors are more effective at priming mucosal immune responses to HIV-1 antigens, than parenteral HIV-1 DNA vaccines. We will address our central hypothesis and reach the long-term goal of this proposal by completing the following specific aims: 1. To construct DNA vaccines that co-express an HIV-1 antigen and a mucosal adjuvant; 2: Identify a Salmonella HIV-1 DNA vaccine that elicits durable humoral and cellular responses to HIV-l in the mucosal and systemic immune compartments; 3. To determine whether preexisting immunity against Salmonella reduces the immunogenicity of Salmonella HIV-1 DNA vaccine vectors; 4: To measure the immunogenicity of an array of prime-boost vaccination protocols using selected Salmonella vector constructs developed in aims 1 through 3. Overall, we believe that the studies proposed herein will further advance this vector system toward widespread clinical application in developing and developed countries.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a Bacteriophage Vaccine Vector System
  • 批准号:
    7659340
  • 项目类别:
  • 资助金额:
    $30.9万
  • 财政年份:
    2009
  • 负责人:
    David Michael Hone
  • 依托单位:
Improved Bladder Cancer Therapy With Recombinant BCG
  • 批准号:
    7326545
  • 项目类别:
  • 资助金额:
    $25.39万
  • 财政年份:
    2007
  • 负责人:
    David Michael Hone
  • 依托单位:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
  • 批准号:
    7277571
  • 项目类别:
  • 资助金额:
    $23.05万
  • 财政年份:
    2003
  • 负责人:
    David Michael Hone
  • 依托单位:
Optimization of Salmonelle-HIV-1 DNA Vaccine Vectors
  • 批准号:
    6867374
  • 项目类别:
  • 资助金额:
    $38.75万
  • 财政年份:
    2003
  • 负责人:
    David Michael Hone
  • 依托单位:
海外基金